Associated Papers
Evaluation of the rapid Idylla IDH1-2 mutation assay in FFPE glioma samples.
Solomon JP et al.
Diagnostic Pathology, 2024
38796421 (PubMed )
Supplement: 13000_2024_1492_MOESM1_ESM.docx
Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
Bill M et al.
Blood Advances, 2023
35381077 (PubMed )
Supplement: BLOODA_ADV-2021-005789-mmc1.pdf
Mutational landscape and genetic signatures of cell-free DNA in tumour-induced osteomalacia.
Wu N et al.
Journal of Cellular and Molecular Medicine, 2020
32277576 (PubMed )
Supplement: JCMM-24-4931-s008.xlsx › Sheet1
Advances in sarcoma gene mutations and therapeutic targets.
Gao P et al.
Cancer Treatment Reviews, 2018
Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS et al.
Neuro-oncology, 2016
Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
Putra J et al.
Experimental and Molecular Pathology, 2015
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
Zou Y et al.
Biochemical and Biophysical Research Communications, 2010
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
Bleeker FE et al.
Human Mutation, 2009
Select a paper to view details